z1b
Introduction
Hims & Hers (NYSE:HIMS) — the hypergrowth telehealth company on a mission to make the world feel great through the power of better health — is going bananas.
Since its bottom in May 2022, the stock has run
Hims & Hers: A Generational Dip-Buying Opportunity
Summary
- HIMS stock is going bananas with the stock up nearly 200% YTD at one point.
- However, the stock sold off due to the FDA's announcement that semaglutide will be taken off the shortage list.
- While bears focus on waning GLP-1 sales, HIMS' business outside GLP-1s is still growing rapidly.
- The company's recent acquisitions unlock massive TAM expansion for the company.
- Despite being up 79% YTD, HIMS stock is still undervalued. In addition, I'm raising my price target on HIMS.
My goal is to help you find the companies of tomorrow.I am a long-term growth investor in search of innovative companies that make the world a better place. My investment strategy revolves around finding what I call "divergent stocks" — disruptive companies that have strong fundamentals and long growth runways, but depressing prices.You can find me on YouTube as well:https://www.youtube.com/@riyadosofian
Analyst’s Disclosure: I/we have a beneficial long position in the shares of HIMS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.